Clinical trialNCT06635785RecruitingPhase 1/PHASE2Interventional

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

SponsorOncoC4, Inc.Enrollment387Advanced Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Kai He, MD, PhD
The Ohio State University James Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Recruiting
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Recruiting
University of Florida Uf Health Cancer Center
Gainesville, Florida, United States
Recruiting
Memorial Healthcare System
Hollywood, Florida, United States
Recruiting
Ocala Oncology Center Pl Dba Florida Cancer Affiliates
Ocala, Florida, United States
Recruiting
Adventhealth Cancer Institute
Orlando, Florida, United States
Recruiting
Northwestern University
Chicago, Illinois, United States
Recruiting
Norton Cancer Center
Louisville, Kentucky, United States
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Recruiting
Henry Ford Health
Detroit, Michigan, United States
Recruiting
the Tisch Cancer Institute, Mount Sinai Medical Center
New York, New York, United States
Recruiting
University of North Carolina at Chapel Hill Cancer Center
Chapel Hill, North Carolina, United States
Recruiting
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, United States
Recruiting
Novant Health Cancer Institute
Winston-Salem, North Carolina, United States
Recruiting
the Ohio State University James Cancer Center
Columbus, Ohio, United States
Recruiting
Prisma Health
Greenville, South Carolina, United States
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Recruiting
University of Texas Health San Antonio Mays Cancer Center
San Antonio, Texas, United States
Recruiting
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AI-081

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Mar 2025
Primary completion: 30 Jun 2027
Completion: 31 Dec 2027
Last update posted: 17 Aug 2026
Registered enrollment: 387
Registry id: NCT06635785

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.